AALL1631: International Phase 3 trial in Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) testing Imatinib in combination with two different cytotoxic chemotherapy backbones
This phase 3 study is examining the best treatments for Philadelphia chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). The goal of this study is to see if using a less toxic chemotherapy regimen in combination with Imatinib can effectively treat standard risk Ph+ ALL. Patients with high risk Ph+ ALL will receive more intensive chemotherapy followed by stem cell transplant.
Are you Eligible? (Inclusion Criteria)
- must be at least greater than 1 year and less than 21 years of age
- Patients must be newly diagnosed
- Patients must also meet all eligibility criteria as outlined in the study protocol